Company: PHAT
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057326
Chunk: 45

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 45
---
 incremental fair value of replacement RSUs granted to Ms. Curran and Dr. Nabulsi in 2023 in connection with the Option Exchange (as defined below) compared to the surrender date fair value of surrendered options in the amount of $355,957 and $200,066, respectively. For additional information on the RSUs granted in connection with the Option Exchange, see the "Outstanding Equity Awards at Fiscal Year-End" table below. These amounts do not reflect whether the recipient has actually realized or will realize a financial benefit from the awards (such as by exercising stock options). Whether, and to what extent, a named executive officer realizes a financial benefit from the awards will depend on our actual operating performance, stock price fluctuations and the named executive officer's continued employment or service. (2) This column reflects the annual bonuses paid to our named executive officers for 2024 and 2023. (3) Includes the value of matching contributions to the 401(k) Plan in the form of fully vested shares of our common stock. Narrative Disclosure to Compensation Tables The primary elements of compensation for our NEOs are base salary, annual bonuses and long-term incentive awards in the form of equity awards. The NEOs also participate in employee benefit plans and programs that we offer to our other employees, as described below. Compensation Determination Process Role of the Compensation Committee The compensation committee of our board of directors develops, reviews and approves each of the elements of our executive compensation program and makes recommendations to our board of directors with respect to non-employee director compensation. The compensation committee also regularly assesses the effectiveness and competitiveness of our compensation programs applicable to all of our employees generally. In the first quarter of each year, the compensation committee reviews the performance of each of our named executive officers during the previous year. At this time the compensation committee also reviews our performance relative to the corporate performance goals set for the year under review and makes the final bonus payment determinations based on our overall corporate performance. In connection with this review, the compensation committee also reviews and adjusts, as appropriate, annual base salaries and target bonuses for our named executive officers and grants, as appropriate, annual equity awards to our named executive officers. Role of our Executive Officers Our Chief Executive Officer and Chief People Officer aid the compensation committee by providing recommendations regarding the compensation of all of our named executive officers, other than themselves. The

<div align='center'>31</div>

compensation committee considers, but is not bound to accept, these recommendations. Our Chief Executive Officer and Chief People Officer